Result of Magnetic Resonance Imaging(MRI) Fusion Transperineal Prostate Biopsy in Patient with Persistent Elevated Prostate Specific Antigen Levels and Prior Negative Random Transrectal Ultrasound (TRUS) Guided Biopsy in Maharaj Nakhon Si Thammarat Hospit
Keywords:
MRI fusion prostate biopsy, Prostate cancerAbstract
Background: Conventional biopsy fails to detect the presence of some prostate cancers(PCas). Repeatedly negative prostate biopsies in individuals with elevated prostate specific antigen (PSA) levels can be frustrating for both the patient and the urologist. Magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy has shown encouraging results for detecting clinically significant prostate cancer.
Objectives: This study was performed to determine the result of magnetic resonance imaging (MRI) fusion transperineal prostate biopsy and complication in patients with persistently elevated prostate specific antigen levels and prior negative random transrectal ultrasound (TRUS) guided biopsy at Maharaj Nakhon Si Thammarat Hospital,Thailand.
Materials and Methods: A retrospective study was conducted by reviewing medical records patients were underwent Magnetic resonance imaging(MRI) targeted, transrectal ultrasound guided transperineal fusion biopsy with persistently elevated prostate-specific antigen(PSA) levels and prior negative random transrectal ultrasound (TRUS) guided biopsy during June 1st, 2022 to July 31th, 2024 in Maharaj Nakhon Si Thammarat Hospital.
Results: Magnetic resonance imaging (MRI) fusion transperineal prostate biopsy can detected prostate cancer 9 in 27 patient(33%) with prior negative random transrectal ultrasound (TRUS) guided biopsy.
Conclusion: Magnetic resonance imaging(MRI) fusion transperineal prostate biopsy can detect significant prostate cancer and small lesion with lower complication.
References
Lojanapiwat B. Urologic cancer in Thailand. Jpn J Clin Oncol 2015;45:1007-15.
Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11.
Kuru TH, Roethke MC, Seidenader J, Simpfendorfer T, Boxler S, Alammar K, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol 2013;190:1380-86.
Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, et al: Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013; 63: 125.
Kasivisvanathan V, Dufour R, Moore CM, Hashim U, Ahmed, Alazeez MA, et al: Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol 2012; 189: 860.
Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62:902-9.
Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012;62:986-96.
Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol 2014;65:809-15.
Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012;188:2152-7.
Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012;30:213- 8.
Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010;16:1875-83.
Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006;50:738-748; discussion 739-48.
Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN, et al. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol 2013;190:1721-7.
Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MGM. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 2015;68:438-50.
Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis. 2022;25(2):256-63.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในมหาราชนครศรีธรรมราชเวชสาร ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใด ๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในมหาราชนครศรีธรรมราชเวชสาร ถือเป็นลิขสิทธิ์ของมหาราชนครศรีธรรมราชเวชสาร หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใด จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษรจากวารสารมหาราชนครศรีธรรมราชเวชสาร ก่อนเท่านั้น
